Research progress on the treatment of newly diagnosed B cell-acute lymphocytic leuk-emia in different age groups with Blinatumomab
10.12354/j.issn.1000-8179.2024.20240253
- VernacularTitle:Blinatumomab治疗不同年龄段新诊断急性B淋巴细胞白血病的研究进展
- Author:
Li XUEYUAN
1
;
Zhou LUKUN
;
Feng SIZHOU
Author Information
1. 天津医科大学,细胞生态海河实验室(天津市 300070)
- Keywords:
Blinatumomab;
acute lymphoblastic leukemia(ALL);
immunotherapy
- From:
Chinese Journal of Clinical Oncology
2024;51(5):258-263
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,interest in exploring the potential of Blinatumomab for treatment of B-cell acute lymphoblastic leukemia(B-ALL)at earlier stages has grown.This is because Blinatumomab has shown promising results in the management of refractory/relapsed(R/R)B-ALL and minimal residual disease(MRD).Blinatumomab has shown comparable efficacy to that of conventional chemotherapy as an altern-ative to consolidation or intensive chemotherapy in pediatric B-ALL patients.Moreover,its use as consolidation therapy or in combination with chemotherapy/targeted therapy,especially in combination with third-generation tyrosine kinase inhibitors(TKIs),shows significant promise for improving prognosis for adult B-ALL patients.This may potentially reduce reliance on allogeneic hematopoietic stem cell trans-plantation(allo-HSCT)in Philadelphia chromosome-positive(Ph+)B-ALL patients.Moreover,Blinatumomab is safer,gentler,and more effect-ive than chemotherapy for older adult patients.Effective therapy options are not yet available for infants with KMT2A rearrangement B-ALL;however,preliminary research indicates that Blinatumomab may offer a breakthrough for this subgroup.In this article,we review progress in investigations of Blinatumomab use in newly diagnosed B-ALL patients.
